Wegovy's release on the 15th…competitor Mounjaro
By Whang, byung-woo | translator Alice Kang
24.10.08 05:55:27
가나다라
0
Ozempic, Wegovy to be used separately for diabetes and obesity indications, respectively…Mounjaro used for both indications
Lilly seeks to adopt strategies to accelerate its product’s market entry
Mounjaro expected to be released in the first half of next year, seeks potential distribution partners
With the release of Wegovy, the next-generation obesity drug, set for the middle of this month (October), the release of its competitor Mounjaro is also gaining attention.
Although Lilly has not yet announced a specific launch date for its Mounjaro, the company has opted to add another indication to its drug rather than apply for new drug approval, which is raising expectations on the company’s early launch scenario.
▲Pic of Mounjaro
Novo Nordisk recently announced that it will launch Wegovy (semaglutide) in the Korean market from the 15th of this month. This will be the 9th global launch in a year and a half since the drug was approved by the Ministry of Food and Drug Safety in April last year.
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)